Due to the known effects of Alpha-1 antitrypsin (A1AT) on signaling pathways and targets affected by diabetic retinopathy in RGCs and in other cells, tissues or pathologies, we also propose it as a new therapeutic approach to delay, reduce or avoid RGC loss (Table 1). The gene discussed is SERPINA1; the disease is diabetic retinopathy.